Using advanced imaging to detect small bowel neuroendocrine tumors
Evaluation of 68Ga-DOTATOC PET/CT-enterography for the Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel
NA · European Institute of Oncology · NCT06773624
This study is testing a new imaging method to see if it can better find small bowel neuroendocrine tumors in patients, helping doctors decide on the best treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 18 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Institute of Oncology (other) |
| Locations | 1 site (Milan) |
| Trial ID | NCT06773624 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of 68Ga-DOTATOC PET/CT-enterography in identifying primary lesions in patients with small bowel neuroendocrine tumors. The study focuses on the importance of accurate staging and evaluation of disease burden, which are critical for determining appropriate treatment options. By utilizing a radiolabeled peptide that targets somatostatin receptors, the trial aims to improve imaging techniques compared to conventional methods. The goal is to enhance the detection of metastatic disease and tumor grading, which are vital prognostic factors.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with small bowel neuroendocrine tumors who are eligible for surgical resection.
Not a fit: Patients with other synchronous oncological diseases or those not eligible for surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses and better treatment planning for patients with small bowel neuroendocrine tumors.
How similar studies have performed: Other studies utilizing similar imaging techniques have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with small bowel neuroendocrine tumours * tumors with any grade (from 1 to 3) and any Ki 67 percentage * patients eligible for surgical resection Exclusion Criteria: * patients with synchronous other oncological disease * patients with Inflammatory bowel disease * patients Not eligible for surgery
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (RECRUITING)
Study contacts
- Study coordinator: Luigi Funicelli, MD
- Email: luigi.funicelli@ieo.it
- Phone: +390294372725
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Small Bowel Neoplasia, Neuroendocrine Tumors